Thus, XPO1 inhibition is effective independent of the TP53 status as we have shown here, consistent with what has been previously shown for sarcoma, non-small cell lung cancer, multiple myeloma, and mesothelioma [29–32]. Here, TP53 is linked to sarcoma.